The University of Chicago Header Logo

Connection

George Bakris to Blood Pressure

Back to Details
This is a "connection" page, showing publications George Bakris has written about Blood Pressure.
George Bakris
Connection Strength
30.871
Blood Pressure
  1. Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study. Hypertension. 2021 07; 78(1):74-81.
    View in: PubMed
    Score: 0.534
  2. Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study. Am J Nephrol. 2020; 51(3):249-254.
    View in: PubMed
    Score: 0.488
  3. Similarities and Differences Between the ACC/AHA and ESH/ESC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circ Res. 2019 03 29; 124(7):969-971.
    View in: PubMed
    Score: 0.461
  4. Ambulatory Blood Pressure Monitoring. JAMA. 2018 Nov 06; 320(17):1807-1808.
    View in: PubMed
    Score: 0.449
  5. MY APPROACH to the elderly patient with resistant hypertension. Trends Cardiovasc Med. 2018 01; 28(1):79-80.
    View in: PubMed
    Score: 0.416
  6. Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"? Am J Hypertens. 2017 Sep 01; 30(9):841-846.
    View in: PubMed
    Score: 0.413
  7. Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations. Circ J. 2017 Aug 25; 81(9):1337-1345.
    View in: PubMed
    Score: 0.404
  8. Response by Bakris to Letter Regarding Article, "The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure". Circulation. 2017 02 14; 135(7):e47.
    View in: PubMed
    Score: 0.398
  9. Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2017 01; 26(1):50-55.
    View in: PubMed
    Score: 0.395
  10. Diabetes: Blood pressure goals in T2DM - time for a rethink? Nat Rev Endocrinol. 2016 11; 12(11):629-630.
    View in: PubMed
    Score: 0.388
  11. The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure. Circulation. 2016 09 27; 134(13):904-5.
    View in: PubMed
    Score: 0.386
  12. From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century. Lancet. 2016 Jul 30; 388(10043):530-2.
    View in: PubMed
    Score: 0.371
  13. Hydrochlorothiazide as the Diuretic of Choice for Hypertension: Time to Kick the Habit. J Am Coll Cardiol. 2016 Feb 02; 67(4):390-391.
    View in: PubMed
    Score: 0.370
  14. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension. 2015 Dec; 66(6):1130-7.
    View in: PubMed
    Score: 0.362
  15. Summary and Conclusions. High Blood Press Cardiovasc Prev. 2015 Jul; 22 Suppl 1:S23.
    View in: PubMed
    Score: 0.356
  16. Update on blood pressure goals in diabetes mellitus. Curr Cardiol Rep. 2015 Jun; 17(6):37.
    View in: PubMed
    Score: 0.354
  17. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015 Apr 07; 65(13):1314-1321.
    View in: PubMed
    Score: 0.350
  18. Reply: A mechanistic explanation for the minimal impact of renal denervation on 24-h ambulatory blood pressure in SIMPLICITY HTN-3. J Am Coll Cardiol. 2015 Mar 10; 65(9):959-60.
    View in: PubMed
    Score: 0.348
  19. Endothelin antagonism and hypertension: an evolving target. Semin Nephrol. 2015 Mar; 35(2):168-75.
    View in: PubMed
    Score: 0.347
  20. The future of renal denervation in resistant hypertension. Curr Hypertens Rep. 2014 Dec; 16(12):494.
    View in: PubMed
    Score: 0.342
  21. In search for the 'sweet spot' for blood pressure level in diabetes. Heart. 2014 Sep 15; 100(18):1404-5.
    View in: PubMed
    Score: 0.334
  22. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014 Sep 16; 64(11):1071-8.
    View in: PubMed
    Score: 0.329
  23. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014 May; 8(5):330-9.
    View in: PubMed
    Score: 0.323
  24. Early patterns of blood pressure change and future coronary atherosclerosis. JAMA. 2014 Feb 05; 311(5):471-2.
    View in: PubMed
    Score: 0.323
  25. Renal denervation and left ventricular mass regression: a benefit beyond blood pressure reduction? J Am Coll Cardiol. 2014 May 13; 63(18):1924-5.
    View in: PubMed
    Score: 0.319
  26. Review of blood pressure control rates and outcomes. J Am Soc Hypertens. 2014 Feb; 8(2):127-41.
    View in: PubMed
    Score: 0.319
  27. Chronic kidney disease: optimal blood pressure for kidney disease-lower is not better. Nat Rev Nephrol. 2013 Nov; 9(11):634-5.
    View in: PubMed
    Score: 0.315
  28. Interventional cardiology: Indications for renal denervation: a balanced approach? Nat Rev Cardiol. 2013 Aug; 10(8):434-6.
    View in: PubMed
    Score: 0.308
  29. Lowering blood pressure limits in patients with type 2 diabetes: is it still warranted? J Diabetes Complications. 2013 Sep-Oct; 27(5):415-6.
    View in: PubMed
    Score: 0.306
  30. Efficacy of baroreflex activation therapy for the treatment of resistant hypertension. EuroIntervention. 2013 May; 9 Suppl R:R136-9.
    View in: PubMed
    Score: 0.306
  31. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich). 2013 Jul; 15(7):473-9.
    View in: PubMed
    Score: 0.306
  32. Clinical guidelines: blood pressure goals in T2DM: a Latin American perspective. Nat Rev Endocrinol. 2013 Mar; 9(3):138-9.
    View in: PubMed
    Score: 0.301
  33. Approaches for targeting blood pressure control in sleep disorders. Curr Opin Nephrol Hypertens. 2012 Sep; 21(5):469-74.
    View in: PubMed
    Score: 0.292
  34. Can ambulatory blood pressure serve as a biomarker for presence of chronic kidney disease? J Hypertens. 2012 Mar; 30(3):466-7.
    View in: PubMed
    Score: 0.282
  35. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012 Mar-Apr; 6(2):152-8.
    View in: PubMed
    Score: 0.281
  36. Hypertension in 2011: New insights--from risk factors to treatment implications. Nat Rev Cardiol. 2011 Dec 13; 9(2):75-7.
    View in: PubMed
    Score: 0.278
  37. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes Obes Metab. 2012 Feb; 14(2):181-6.
    View in: PubMed
    Score: 0.276
  38. Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage? Curr Opin Nephrol Hypertens. 2011 Sep; 20(5):471-5.
    View in: PubMed
    Score: 0.273
  39. CON: blood pressure treatment goal for patients with diabetes should be <130/80 mm Hg. J Clin Hypertens (Greenwich). 2011 Apr; 13(4):263-5.
    View in: PubMed
    Score: 0.265
  40. Blood pressure targets in diabetes: is this the time for change?--CON (Rebuttal). J Clin Hypertens (Greenwich). 2011 Apr; 13(4):268-9.
    View in: PubMed
    Score: 0.265
  41. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011 Feb; 13(2):81-8.
    View in: PubMed
    Score: 0.262
  42. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010 Nov; 56(5):824-30.
    View in: PubMed
    Score: 0.256
  43. Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study. J Clin Hypertens (Greenwich). 2010 Sep; 12(9):678-86.
    View in: PubMed
    Score: 0.252
  44. Pediatrics: blood pressure target for renoprotection in children. Nat Rev Nephrol. 2010 Feb; 6(2):67-8.
    View in: PubMed
    Score: 0.244
  45. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol. 2010 Jan 04; 105(1 Suppl):21A-9A.
    View in: PubMed
    Score: 0.243
  46. Hypertension goals in advanced-stage kidney disease. Clin J Am Soc Nephrol. 2009 Dec; 4 Suppl 1:S92-4.
    View in: PubMed
    Score: 0.242
  47. The future of blood pressure control in a population with a growing girth. Curr Opin Nephrol Hypertens. 2009 Sep; 18(5):379-80.
    View in: PubMed
    Score: 0.237
  48. Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible? J Clin Hypertens (Greenwich). 2009 Jul; 11(7):345-7.
    View in: PubMed
    Score: 0.235
  49. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J Cardiovasc Pharmacol. 2009 May; 53(5):379-87.
    View in: PubMed
    Score: 0.232
  50. Assessing blood pressure control in dialysis patients: finally a step forward. Hypertension. 2009 Mar; 53(3):448-9.
    View in: PubMed
    Score: 0.227
  51. Influence of microalbuminuria in achieving blood pressure goals. Curr Opin Nephrol Hypertens. 2008 Sep; 17(5):457-63.
    View in: PubMed
    Score: 0.221
  52. ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich). 2008 Sep; 10(9):707-13; discussion 714-5.
    View in: PubMed
    Score: 0.221
  53. Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich). 2008 Feb; 10(2):112-8.
    View in: PubMed
    Score: 0.213
  54. Pulse pressure and arterial stiffness: an emerging renal risk predictor? J Hypertens. 2007 Sep; 25(9):1796-7.
    View in: PubMed
    Score: 0.207
  55. Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study. J Hum Hypertens. 2007 May; 21(5):347-52.
    View in: PubMed
    Score: 0.200
  56. Improving blood pressure control rates: is there more we can do? J Clin Hypertens (Greenwich). 2007 Feb; 9(2):134-42.
    View in: PubMed
    Score: 0.198
  57. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006 Oct; 24(10):2047-55.
    View in: PubMed
    Score: 0.194
  58. Insulin resistance, hyperinsulinemia, and hypertension: an epidemiologic approach. J Cardiometab Syndr. 2006; 1(5):334-42; quiz 343.
    View in: PubMed
    Score: 0.184
  59. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich). 2005 Jun; 7(6):354-6.
    View in: PubMed
    Score: 0.177
  60. ACE inhibitor for a diabetic patient with normal blood pressure? Postgrad Med. 2005 Jan; 117(1):6.
    View in: PubMed
    Score: 0.172
  61. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024 03 05; 331(9):740-749.
    View in: PubMed
    Score: 0.162
  62. Overview of the Evolution of Hypertension: From Ancient Chinese Emperors to Today. Hypertension. 2024 Apr; 81(4):717-726.
    View in: PubMed
    Score: 0.162
  63. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 2004 Mar; 43(3):573-7.
    View in: PubMed
    Score: 0.161
  64. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023 Jul 20; 389(3):228-238.
    View in: PubMed
    Score: 0.155
  65. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023 08; 25(8):737-747.
    View in: PubMed
    Score: 0.155
  66. Novel Therapies on the Horizon of Hypertension Management. Am J Hypertens. 2023 02 13; 36(2):73-81.
    View in: PubMed
    Score: 0.151
  67. Newer alternatives for resistant hypertension: Beyond 2022 paradigms. Hellenic J Cardiol. 2023 Mar-Apr; 70:75-77.
    View in: PubMed
    Score: 0.150
  68. Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans. Curr Opin Nephrol Hypertens. 2003 Jan; 12(1):79-84.
    View in: PubMed
    Score: 0.150
  69. Longitudinal Blood Pressure Patterns and Chronic Kidney Disease Progression: An Evolving Paradigm. Hypertension. 2021 11; 78(5):1365-1367.
    View in: PubMed
    Score: 0.137
  70. Approach to Resistant Hypertension from Cardiology and Nephrology Standpoints: Tailoring Therapy. Cardiol Clin. 2021 Aug; 39(3):377-387.
    View in: PubMed
    Score: 0.136
  71. Systolic Blood Pressure During Exercise Testing: Where the Valley Means More Than the Peak. Hypertension. 2021 06; 77(6):1915-1917.
    View in: PubMed
    Score: 0.133
  72. Time in Therapeutic Range: Redefining "Optimal" Blood Pressure Control. J Am Coll Cardiol. 2021 03 16; 77(10):1300-1301.
    View in: PubMed
    Score: 0.132
  73. Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It? Diabetes Care. 2020 08; 43(8):1684-1686.
    View in: PubMed
    Score: 0.126
  74. Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther. 2000 Jun; 14(3):295-301.
    View in: PubMed
    Score: 0.125
  75. Fear of Lowering Cardiovascular Risk by Achieving Blood Pressure Goals: The Irrationality of Combination Therapy Avoidance. Hypertension. 2020 04; 75(4):943-944.
    View in: PubMed
    Score: 0.123
  76. Assessing Wide Pulse Pressure Hypertension: Data Beyond the Guidelines. J Am Coll Cardiol. 2019 06 11; 73(22):2856-2858.
    View in: PubMed
    Score: 0.117
  77. The Management of Hypertension in 2018: What Should the Targets Be? Curr Hypertens Rep. 2019 04 25; 21(6):41.
    View in: PubMed
    Score: 0.116
  78. The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients. Nephrol Dial Transplant. 2019 03 01; 34(3):515-523.
    View in: PubMed
    Score: 0.115
  79. Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis. Curr Hypertens Rep. 2019 02 12; 21(2):12.
    View in: PubMed
    Score: 0.114
  80. Controversies in the 2017 ACC/AHA Hypertension Guidelines: Who Can Be Eligible for Treatments Under the New Guidelines? - An Asian Perspective. Circ J. 2019 02 25; 83(3):504-510.
    View in: PubMed
    Score: 0.113
  81. Creatinine Bump Following Antihypertensive Therapy. Hypertension. 2018 12; 72(6):1274-1276.
    View in: PubMed
    Score: 0.113
  82. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 11; 72(5):e53-e90.
    View in: PubMed
    Score: 0.112
  83. Renal denervation: one step backwards, three steps forward. Nat Rev Nephrol. 2018 10; 14(10):602-604.
    View in: PubMed
    Score: 0.111
  84. Has the Sun Set on Nighttime Dosing in Uncomplicated Hypertension? Hypertension. 2018 10; 72(4):836-838.
    View in: PubMed
    Score: 0.111
  85. Presence of Diabetes Does Not Mandate Lower Blood Pressure to Reduce Cardiovascular Events. J Am Coll Cardiol. 2018 09 11; 72(11):1224-1226.
    View in: PubMed
    Score: 0.111
  86. Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations. JAMA. 2018 Apr 03; 319(13):1319-1320.
    View in: PubMed
    Score: 0.108
  87. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment. J Hypertens. 2018 04; 36(4):720-733.
    View in: PubMed
    Score: 0.108
  88. Progression of diabetic nephropathy. A focus on arterial pressure level and methods of reduction. Diabetes Res Clin Pract. 1998 Apr; 39 Suppl:S35-42.
    View in: PubMed
    Score: 0.108
  89. Blood pressure reduced to new guideline goals in patients with high-normal glucose further reduces cardiovascular events. J Clin Hypertens (Greenwich). 2018 04; 20(4):625-626.
    View in: PubMed
    Score: 0.107
  90. SGLT2 Inhibitors and Mechanisms of Hypertension. Curr Cardiol Rep. 2018 01 19; 20(1):1.
    View in: PubMed
    Score: 0.106
  91. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1).
    View in: PubMed
    Score: 0.106
  92. Initial Single-Pill Blood Pressure-Lowering Therapy: Should It Be for Most People? J Am Heart Assoc. 2017 11 18; 6(11).
    View in: PubMed
    Score: 0.105
  93. Consequences of Overinterpreting Serum Creatinine Increases when Achieving BP Reduction: Balancing Risks and Benefits of BP Reduction in Hypertension. Clin J Am Soc Nephrol. 2018 01 06; 13(1):9-10.
    View in: PubMed
    Score: 0.105
  94. High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. Am Heart J. 2017 Oct; 192:76-84.
    View in: PubMed
    Score: 0.102
  95. Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. J Clin Hypertens (Greenwich). 2017 Jul; 19(7):695-701.
    View in: PubMed
    Score: 0.101
  96. Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. J Am Soc Nephrol. 2017 Sep; 28(9):2794-2801.
    View in: PubMed
    Score: 0.101
  97. Treatment of renal failure and blood pressure. Curr Opin Nephrol Hypertens. 1997 May; 6(3):237-42.
    View in: PubMed
    Score: 0.101
  98. Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. Hypertension. 2017 May; 69(5):836-843.
    View in: PubMed
    Score: 0.100
  99. Searching for the Optimal Blood Pressure Range in the Elderly: Are We There Yet? J Am Coll Cardiol. 2017 02 07; 69(5):494-496.
    View in: PubMed
    Score: 0.099
  100. On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension. Hypertension. 2017 02; 69(2):220-227.
    View in: PubMed
    Score: 0.099
  101. The Kidney in Hypertension. Med Clin North Am. 2017 Jan; 101(1):207-217.
    View in: PubMed
    Score: 0.099
  102. Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? Am J Hypertens. 1996 Dec; 9(12 Pt 2):200S-206S.
    View in: PubMed
    Score: 0.098
  103. Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial. Circ J. 2016 May 25; 80(6):1404-12.
    View in: PubMed
    Score: 0.094
  104. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016 Apr; 34(4):788-97.
    View in: PubMed
    Score: 0.094
  105. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307.
    View in: PubMed
    Score: 0.094
  106. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Blood Purif. 2016; 41(1-3):139-43.
    View in: PubMed
    Score: 0.092
  107. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015 Oct 17; 386(10003):1588-98.
    View in: PubMed
    Score: 0.091
  108. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 01; 314(9):884-94.
    View in: PubMed
    Score: 0.090
  109. Renal denervation for resistant hypertension and beyond. Adv Chronic Kidney Dis. 2015 Mar; 22(2):133-9.
    View in: PubMed
    Score: 0.087
  110. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015 Mar; 38(3):429-30.
    View in: PubMed
    Score: 0.087
  111. Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease. J Am Soc Hypertens. 2015 Apr; 9(4):299-306.
    View in: PubMed
    Score: 0.087
  112. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014; 40(6):572-81.
    View in: PubMed
    Score: 0.086
  113. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015 Jan 21; 36(4):219-27.
    View in: PubMed
    Score: 0.085
  114. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014; 40(1):64-74.
    View in: PubMed
    Score: 0.083
  115. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. Adv Chronic Kidney Dis. 2014 May; 21(3):281-6.
    View in: PubMed
    Score: 0.082
  116. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014 Apr; 19(2):90-7.
    View in: PubMed
    Score: 0.082
  117. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.
    View in: PubMed
    Score: 0.081
  118. The future of interventional management of hypertension: threats and opportunities. Curr Vasc Pharmacol. 2014 Jan; 12(1):69-76.
    View in: PubMed
    Score: 0.080
  119. Sympathetic activation in resistant hypertension: theory and therapy. Semin Nephrol. 2014; 34(5):550-9.
    View in: PubMed
    Score: 0.080
  120. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications. 1994 Jan-Mar; 8(1):2-6.
    View in: PubMed
    Score: 0.080
  121. Role of ambulatory blood pressure monitoring in hypertension and diabetes. Curr Hypertens Rep. 2013 Jun; 15(3):137-42.
    View in: PubMed
    Score: 0.077
  122. Association of BP variability with mortality among African Americans with CKD. Clin J Am Soc Nephrol. 2013 May; 8(5):731-8.
    View in: PubMed
    Score: 0.076
  123. Hypertensive goals in patients with coronary artery disease. Curr Cardiol Rep. 2012 Dec; 14(6):667-72.
    View in: PubMed
    Score: 0.074
  124. A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension. 2013 Jan; 61(1):82-8.
    View in: PubMed
    Score: 0.074
  125. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013 Feb; 15(2):92-100.
    View in: PubMed
    Score: 0.074
  126. Management of hypertension in the elderly population. J Gerontol A Biol Sci Med Sci. 2012 Dec; 67(12):1343-51.
    View in: PubMed
    Score: 0.073
  127. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012 Sep; 35(9):528-35.
    View in: PubMed
    Score: 0.071
  128. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens. 2012 May; 30(5):874-6.
    View in: PubMed
    Score: 0.071
  129. Kidney dysfunction, cardiorespiratory fitness, and the risk of death in women. J Womens Health (Larchmt). 2012 Sep; 21(9):917-24.
    View in: PubMed
    Score: 0.071
  130. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich). 2012 May; 14(5):284-92.
    View in: PubMed
    Score: 0.071
  131. Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes. Curr Vasc Pharmacol. 2012 Mar; 10(2):156-61.
    View in: PubMed
    Score: 0.071
  132. Blood pressure targets for patients with diabetes or kidney disease. Curr Hypertens Rep. 2011 Dec; 13(6):452-5.
    View in: PubMed
    Score: 0.069
  133. Isolated diastolic hypotension and incident heart failure in older adults. Hypertension. 2011 Nov; 58(5):895-901.
    View in: PubMed
    Score: 0.068
  134. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011 Aug 09; 58(7):765-73.
    View in: PubMed
    Score: 0.068
  135. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):467-72.
    View in: PubMed
    Score: 0.067
  136. Effects of naproxcinod on blood pressure in patients with osteoarthritis. Am J Cardiol. 2011 May 01; 107(9):1338-45.
    View in: PubMed
    Score: 0.066
  137. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar; 57(3):413-20.
    View in: PubMed
    Score: 0.065
  138. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension. 2011 Feb; 57(2):174-9.
    View in: PubMed
    Score: 0.065
  139. Pathogenesis and clinical physiology of hypertension. Cardiol Clin. 2010 Nov; 28(4):545-59.
    View in: PubMed
    Score: 0.064
  140. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother. 2010 Nov; 11(16):2675-86.
    View in: PubMed
    Score: 0.063
  141. Predictors of hypertension control in a diverse general cardiology practice. J Clin Hypertens (Greenwich). 2010 Aug; 12(8):570-7.
    View in: PubMed
    Score: 0.063
  142. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010 Jul 07; 304(1):61-8.
    View in: PubMed
    Score: 0.063
  143. More complete renin-angiotensin system blockade: better outcomes or smoke and mirrors. J Hypertens. 2010 Jul; 28(7):1382-3.
    View in: PubMed
    Score: 0.063
  144. 24-hour ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med. 2010 Jul 01; 363(1):98.
    View in: PubMed
    Score: 0.063
  145. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010 May 05; 102(9):596-604.
    View in: PubMed
    Score: 0.062
  146. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 03; 375(9721):1173-81.
    View in: PubMed
    Score: 0.061
  147. The editor's roundtable: prehypertension. Am J Cardiol. 2009 Oct 15; 104(8):1105-15.
    View in: PubMed
    Score: 0.060
  148. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009; 30(5):418-24.
    View in: PubMed
    Score: 0.059
  149. Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. Diabetes Obes Metab. 2009 Aug; 11(8):757-69.
    View in: PubMed
    Score: 0.058
  150. The kidney, hypertension, and remaining challenges. Med Clin North Am. 2009 May; 93(3):697-715, Table of Contents.
    View in: PubMed
    Score: 0.058
  151. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S22-31.
    View in: PubMed
    Score: 0.058
  152. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S3-10.
    View in: PubMed
    Score: 0.058
  153. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens. 2009 Apr; 27(4):673-9.
    View in: PubMed
    Score: 0.058
  154. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. J Hypertens. 2009 Mar; 27(3):666-9.
    View in: PubMed
    Score: 0.057
  155. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Clin J Am Soc Nephrol. 2009 Mar; 4(3):517-9.
    View in: PubMed
    Score: 0.057
  156. The message for World Kidney Day 2009: hypertension and kidney disease-a marriage that should be prevented. Clin Exp Nephrol. 2009 Feb; 13(1):96-9.
    View in: PubMed
    Score: 0.057
  157. The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. J Hum Hypertens. 2009 Mar; 23(3):222-5.
    View in: PubMed
    Score: 0.057
  158. G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens. 2009 Mar; 22(3):332-8.
    View in: PubMed
    Score: 0.057
  159. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008 Nov 25; 52(22):1749-57.
    View in: PubMed
    Score: 0.056
  160. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008 Aug; 74(3):364-9.
    View in: PubMed
    Score: 0.054
  161. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008 Jun; 73(11):1303-9.
    View in: PubMed
    Score: 0.054
  162. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008 Feb; 51(2):192-8.
    View in: PubMed
    Score: 0.053
  163. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come? J Clin Hypertens (Greenwich). 2008 Feb; 10(2):146-52.
    View in: PubMed
    Score: 0.053
  164. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich). 2008 Jan; 10(1 Suppl 1):27-32.
    View in: PubMed
    Score: 0.053
  165. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008 Jan; 3 Suppl 1:S3-10.
    View in: PubMed
    Score: 0.053
  166. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. J Cardiometab Syndr. 2008; 3(4):229-33.
    View in: PubMed
    Score: 0.053
  167. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich). 2007 Nov; 9(11):842-9.
    View in: PubMed
    Score: 0.052
  168. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007 Oct; 25(10):2082-92.
    View in: PubMed
    Score: 0.052
  169. Should beta-blockers be used to control hypertension in people with chronic kidney disease? Semin Nephrol. 2007 Sep; 27(5):555-64.
    View in: PubMed
    Score: 0.052
  170. Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial. Pol Arch Med Wewn. 2007 Sep; 117(9):389-90.
    View in: PubMed
    Score: 0.052
  171. ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression? J Clin Hypertens (Greenwich). 2007 Jun; 9(6):413-5.
    View in: PubMed
    Score: 0.051
  172. Microalbuminuria: what is it? Why is it important? What should be done about it? An update. J Clin Hypertens (Greenwich). 2007 Mar; 9(3):196-200.
    View in: PubMed
    Score: 0.050
  173. Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. Am J Cardiovasc Drugs. 2007; 7 Suppl 1:25-9.
    View in: PubMed
    Score: 0.049
  174. The continuum of blood pressure risk: when is the best time to intervene? Curr Hypertens Rep. 2006 Oct; 8(5):395-7.
    View in: PubMed
    Score: 0.048
  175. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006 Oct; 70(7):1223-33.
    View in: PubMed
    Score: 0.048
  176. Are beta blockers passé for the treatment of hypertension? J Clin Hypertens (Greenwich). 2006 Apr; 8(4):239-40.
    View in: PubMed
    Score: 0.047
  177. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc. 2006 Apr; 98(4):618-26.
    View in: PubMed
    Score: 0.047
  178. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005 Dec; 46(6):1309-15.
    View in: PubMed
    Score: 0.046
  179. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):578-86.
    View in: PubMed
    Score: 0.045
  180. Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):587-95; quiz 596-7.
    View in: PubMed
    Score: 0.045
  181. Hypertension treatment guidelines: practical implications. Semin Nephrol. 2005 Jul; 25(4):198-209.
    View in: PubMed
    Score: 0.044
  182. Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. Blood Press Monit. 2005 Jun; 10(3):157-63.
    View in: PubMed
    Score: 0.044
  183. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005 Jun; 18(6):797-804.
    View in: PubMed
    Score: 0.044
  184. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53.
    View in: PubMed
    Score: 0.044
  185. Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Prev Cardiol. 2005; 8(2):87-92.
    View in: PubMed
    Score: 0.043
  186. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens. 2004 Dec; 17(12 Pt 2):23S-30S.
    View in: PubMed
    Score: 0.043
  187. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens. 2004 Jul; 17(7):590-6.
    View in: PubMed
    Score: 0.041
  188. Is proteinuria a plausible target of therapy? Curr Hypertens Rep. 2004 Jun; 6(3):177-81.
    View in: PubMed
    Score: 0.041
  189. Management of hypertension in the cardiometabolic syndrome and diabetes. Curr Diab Rep. 2004 Jun; 4(3):199-205.
    View in: PubMed
    Score: 0.041
  190. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004 Jun; 65(6):1991-2002.
    View in: PubMed
    Score: 0.041
  191. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. J Hypertens. 2004 Jan; 22(1):217-22.
    View in: PubMed
    Score: 0.040
  192. Hypertension and nephropathy. Am J Med. 2003 Dec 08; 115 Suppl 8A:49S-54S.
    View in: PubMed
    Score: 0.040
  193. Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials. J Am Heart Assoc. 2023 07 04; 12(13):e028516.
    View in: PubMed
    Score: 0.039
  194. Hypertension in Patients Treated With In-Center Maintenance Hemodialysis: Current Evidence and Future Opportunities: A Scientific Statement From the American Heart Association. Hypertension. 2023 06; 80(6):e112-e122.
    View in: PubMed
    Score: 0.038
  195. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023 02 01; 41(2):295-302.
    View in: PubMed
    Score: 0.037
  196. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002 Nov; 20(11):2257-67.
    View in: PubMed
    Score: 0.037
  197. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 2022 12; 79(12):2685-2695.
    View in: PubMed
    Score: 0.037
  198. Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals. Postgrad Med. 2002 Oct; 112(4):73-4, 77-80, 83-4.
    View in: PubMed
    Score: 0.037
  199. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022 10 22; 400(10361):1405-1416.
    View in: PubMed
    Score: 0.037
  200. Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. J Hypertens. 2022 10 01; 40(10):1847-1858.
    View in: PubMed
    Score: 0.036
  201. Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2002 Jul-Aug; 4(4 Suppl 1):26-31.
    View in: PubMed
    Score: 0.036
  202. Evaluation and treatment of patients with systemic hypertension. Circulation. 2002 May 28; 105(21):2458-61.
    View in: PubMed
    Score: 0.036
  203. Pathogenesis and clinical physiology of hypertension. Cardiol Clin. 2002 May; 20(2):195-206, v.
    View in: PubMed
    Score: 0.036
  204. Treatment of Resistant Hypertension With Endovascular Baroreflex Amplification: 3-Year Results From the CALM-FIM Study. JACC Cardiovasc Interv. 2022 02 14; 15(3):321-332.
    View in: PubMed
    Score: 0.035
  205. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens. 2002 Jan; 15(1 Pt 1):53-7.
    View in: PubMed
    Score: 0.035
  206. Untreated Hypertension and Subsequent Incidence of Colorectal Cancer: Analysis of a Nationwide Epidemiological Database. J Am Heart Assoc. 2021 11 16; 10(22):e022479.
    View in: PubMed
    Score: 0.034
  207. Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. Catheter Cardiovasc Interv. 2021 09; 98(3):416-426.
    View in: PubMed
    Score: 0.034
  208. Angiotensin-converting enzyme inhibition to enhance vascular health--clinical and research models. Am J Hypertens. 2001 Aug; 14(8 Pt 2):264S-269S.
    View in: PubMed
    Score: 0.034
  209. Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. Am J Hypertens. 2021 05 22; 34(5):531-539.
    View in: PubMed
    Score: 0.033
  210. Treatment of stage I hypertension and development of renal dysfunction. J Hum Hypertens. 2001 Feb; 15(2):81-4.
    View in: PubMed
    Score: 0.033
  211. Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 12 31; 16(1):59-69.
    View in: PubMed
    Score: 0.032
  212. Evolution of drugs that preserve renal function. J Clin Pharmacol. 2000 Sep; 40(9):978-89.
    View in: PubMed
    Score: 0.032
  213. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000 Sep; 36(3):646-61.
    View in: PubMed
    Score: 0.032
  214. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int. 2000 Apr; 57(4):1651-61.
    View in: PubMed
    Score: 0.031
  215. Hypertension in patients with diabetes. Why is aggressive treatment essential? Postgrad Med. 2000 Feb; 107(2):53-6, 61-4.
    View in: PubMed
    Score: 0.031
  216. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998 Oct; 54(4):1283-9.
    View in: PubMed
    Score: 0.028
  217. The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium. Am J Hypertens. 1998 Oct; 11(10):158S-162S.
    View in: PubMed
    Score: 0.028
  218. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. J Hypertens. 2018 04; 36(4):947-956.
    View in: PubMed
    Score: 0.027
  219. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens. 1997 Oct; 15(10):1181-5.
    View in: PubMed
    Score: 0.026
  220. Calcium antagonism abolishes the antipressor action of vasopressin (V1) receptor antagonism. Am J Hypertens. 1997 Oct; 10(10 Pt 1):1153-8.
    View in: PubMed
    Score: 0.026
  221. Renal components of the hypertensive syndrome. J Cardiovasc Risk. 1997 Aug; 4(4):271-7.
    View in: PubMed
    Score: 0.026
  222. Role of vasopressin in essential hypertension: racial differences. J Hypertens. 1997 May; 15(5):545-50.
    View in: PubMed
    Score: 0.025
  223. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997 Mar; 29(3):744-50.
    View in: PubMed
    Score: 0.025
  224. Socioeconomic impact of diabetic nephropathy: can we improve the outcome? J Hypertens Suppl. 1997 Mar; 15(2):S77-82.
    View in: PubMed
    Score: 0.025
  225. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996 Nov; 50(5):1641-50.
    View in: PubMed
    Score: 0.024
  226. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med. 1996 Sep 23; 156(17):1969-78.
    View in: PubMed
    Score: 0.024
  227. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016 09; 90(3):696-704.
    View in: PubMed
    Score: 0.024
  228. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016 Mar 08; 315(10):990-1004.
    View in: PubMed
    Score: 0.023
  229. CLINICAL DECISIONS. Blood-Pressure Control. N Engl J Med. 2015 Nov 26; 373(22):2180-2.
    View in: PubMed
    Score: 0.023
  230. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol. 1995 Jan; 35(1):73-80.
    View in: PubMed
    Score: 0.021
  231. Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies. J Intern Med. 2015 Jul; 278(1):38-49.
    View in: PubMed
    Score: 0.021
  232. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014 Oct; 16(10):1016-27.
    View in: PubMed
    Score: 0.021
  233. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014 Apr 10; 370(15):1393-401.
    View in: PubMed
    Score: 0.020
  234. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014 Mar; 32(3):635-43.
    View in: PubMed
    Score: 0.020
  235. Proceedings from Duke resistant hypertension think tank. Am Heart J. 2014 Jun; 167(6):775-88.e1.
    View in: PubMed
    Score: 0.020
  236. Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens. 2014 Feb; 32(2):415-22.
    View in: PubMed
    Score: 0.020
  237. Association of cognitive dysfunction with cardiovascular disease events in elderly hypertensive patients. J Hypertens. 2014 Feb; 32(2):423-31.
    View in: PubMed
    Score: 0.020
  238. Effects of antihypertensive treatment in Asian populations: a meta-analysis of prospective randomized controlled studies (CARdiovascular protectioN group in Asia: CARNA). J Am Soc Hypertens. 2014 Feb; 8(2):103-16.
    View in: PubMed
    Score: 0.020
  239. Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA. 2013 Sep 18; 310(11):1135-44.
    View in: PubMed
    Score: 0.020
  240. Both chronic kidney disease and nocturnal blood pressure associate with strokes in the elderly. Am J Nephrol. 2013; 38(3):195-203.
    View in: PubMed
    Score: 0.020
  241. Diabetic nephropathy. Dis Mon. 1993 Aug; 39(8):573-611.
    View in: PubMed
    Score: 0.019
  242. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.
    View in: PubMed
    Score: 0.019
  243. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013 Aug; 62(2):201-13.
    View in: PubMed
    Score: 0.019
  244. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med. 1993 Apr 15; 118(8):643-4.
    View in: PubMed
    Score: 0.019
  245. Hypertension in diabetic patients. An overview of interventional studies to preserve renal function. Am J Hypertens. 1993 Apr; 6(4):140S-147S.
    View in: PubMed
    Score: 0.019
  246. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012 Aug; 60(2):310-8.
    View in: PubMed
    Score: 0.018
  247. Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther. 2012 Mar; 34(3):537-51.
    View in: PubMed
    Score: 0.018
  248. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76.
    View in: PubMed
    Score: 0.017
  249. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352.
    View in: PubMed
    Score: 0.017
  250. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 Sep 02; 363(10):918-29.
    View in: PubMed
    Score: 0.016
  251. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010 Jun 29; 56(1):77-85.
    View in: PubMed
    Score: 0.016
  252. The effects of enalapril on urinary protein excretion in patients with idiopathic membranous nephropathy. J Clin Pharmacol. 1990 Feb; 30(2):155-8.
    View in: PubMed
    Score: 0.015
  253. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010; 31(2):95-103.
    View in: PubMed
    Score: 0.015
  254. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S11-21.
    View in: PubMed
    Score: 0.014
  255. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 04; 359(23):2417-28.
    View in: PubMed
    Score: 0.014
  256. A propensity-matched study of hypertension and increased stroke-related hospitalization in chronic heart failure. Am J Cardiol. 2008 Jun 15; 101(12):1772-6.
    View in: PubMed
    Score: 0.013
  257. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press. 2008; 17(1):7-17.
    View in: PubMed
    Score: 0.013
  258. Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr. 2008; 3(4):211-7.
    View in: PubMed
    Score: 0.013
  259. The editor's roundtable: revisiting the role of beta blockers in hypertension. Am J Cardiol. 2007 Jul 15; 100(2):253-67.
    View in: PubMed
    Score: 0.013
  260. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007 May; 9(5):355-64.
    View in: PubMed
    Score: 0.013
  261. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007; 16(2):80-6.
    View in: PubMed
    Score: 0.012
  262. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006 Dec; 8(12):840-9.
    View in: PubMed
    Score: 0.012
  263. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006 Aug; 8(8):571-81; quiz 582-3.
    View in: PubMed
    Score: 0.012
  264. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006 Jul; 8(7):470-80.
    View in: PubMed
    Score: 0.012
  265. An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements. J Clin Hypertens (Greenwich). 2006 Apr; 8(4):241-50; quiz 251-2.
    View in: PubMed
    Score: 0.012
  266. A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney Int. 1985 Feb; 27(2):465-8.
    View in: PubMed
    Score: 0.011
  267. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 03; 290(21):2805-16.
    View in: PubMed
    Score: 0.010
  268. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec; 42(6):1206-52.
    View in: PubMed
    Score: 0.010
  269. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich). 2003 Sep-Oct; 5(5):322-9.
    View in: PubMed
    Score: 0.010
  270. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens. 2003 Jun; 16(6):460-6.
    View in: PubMed
    Score: 0.010
  271. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21; 289(19):2560-72.
    View in: PubMed
    Score: 0.010
  272. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20; 288(19):2421-31.
    View in: PubMed
    Score: 0.009
  273. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999 May; 55(5):1849-60.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.